u/BioIsLife_PortIsDead · 147d agono track record yet
“Buy shares along with a few $2.5 puts as insurance for a CRL. July $2.5 calls with some puts as a hedge.”
SPRO - 50 Shades of Green
Tebipenem, SPRO's first oral carbapenem for complicated UTIs, has Phase 3 data backed by FDA-agreed SPA, stopped early for overwhelming efficacy, and is expected to secure approval with high confidence. Post-approval, GSK handles commercialization while SPRO collects guaranteed $101M milestones plus sales-based payments and royalties, making execution risk low and upside potential substantial.
At post $2.57Now $1.07-58.4% since postedas of Oct 26, 4:15 PM ET
1d-1.2%
3d+10.9%
1w+7.8%
1m-17.5%
3m-52.9%
6m—
1y—